|
As Heads of State and Government come together for a special summit this week, they have a strategic choice to make: a thriving innovative, research-driven biopharmaceutical ecosystem with world-leading medical science that supports early access to innovation for patients, economic prosperity and European jobs; or a death by degrees: gradual loss of standards in healthcare, investment and talent, enticed across the Atlantic or to the Asia-Pacific region with the promise of a vision, ambition and policy framework that will drive rather than choke medical innovation.
|
